Hepatitis B Virus Perinatal Exposure Follow-up Panel, Serum
Use
This test is intended to determine hepatitis B virus infection and immunity status in infants born to mothers with chronic hepatitis B, whether or not they have received perinatal prophylaxis. It aids in identifying acute or chronic hepatitis B infection and assesses immunity status post-recovery or post-vaccination.
Special Instructions
This test should be ordered specifically for infants born to mothers with chronic hepatitis B. Patient preparation involves avoiding multivitamins or dietary supplements containing biotin for 24 hours before specimen collection. The test may include reflex testing for Hepatitis B surface antigen confirmation if initial results are reactive.
Limitations
Assay performance has not been established for grossly icteric, lipemic, or hemolyzed specimens, or specimens containing particulate matter. It also does not differentiate between a vaccine-induced immune response and recovery from HBV infection. Testing may not be suitable for cadaveric or heat-inactivated specimens.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 77190-7
- 13952-7
- 10900-9
- 5193-8
- 5196-1
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.2 mL
Minimum Volume
0.9 mL
Container
Plastic vial
Collection Instructions
Centrifuge blood collection tube per manufacturer's instructions and aliquot serum into a plastic vial.
Patient Preparation
For 24 hours before specimen collection, patient should not take multivitamins or dietary supplements containing biotin.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 6 days |
| Frozen | 90 days |